抗体偶联药物治疗消化系统肿瘤的研究进展  

The research progress of antibody-drug conjugate therapy in the malignant tumors of digestive system

作　　者：程浩 依荷芭丽·迟 石素胜 CHENG Hao;Yihebali·Chi;SHI Susheng(Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院病理科,北京100021 [2]国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院肿瘤内科,北京100021

出　　处：《现代肿瘤医学》2022年第5期916-922,共7页Journal of Modern Oncology

摘　　要：消化系统肿瘤发病率和病死率较高,对于缺乏手术适应证及放疗、化疗效果不好的患者,亟需发展新型而高效的治疗手段。近年来,抗体-药物偶联物(antibody-drug conjugates,ADC)因其具有抗体药物的高选择性和细胞毒药物的高活性等优点而逐渐成为研究热点,在消化系统肿瘤的治疗中已取得一些成果,但是仍需面对诸多挑战。本文将对新进展进行简要综述。Malignant tumors of digestive system present with relatively high morbidity and mortality.It is urgent to find novel and efficient treatment methods for patients who lack surgical indications or those who with poor radiotherapy and chemotherapy outcomes.Antibody-drug conjugates(ADCs)therapy has gradually become a research hot issue in recent years, with the advantages of both high selectivity of the antibody drug and the activity of cytotoxic drugs.ADCs therapy has made some achievements in the treatment of digestive system neoplasms,but it still needs to face many challenges. Here,we will give a brief review on the recent progress about ADCs in the treatment of tumors of digestive system.

关 键 词：抗体偶联药物 消化系肿瘤 生物学基础 靶向治疗 

分 类 号：R730.53[医药卫生—肿瘤]